Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02061761
Title	Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Bristol-Myers Squibb
Indications	diffuse large B-cell lymphoma Hodgkin's lymphoma non-Hodgkin lymphoma multiple myeloma chronic lymphocytic leukemia
Therapies	Nivolumab + Relatlimab Relatlimab
Age Groups:	adult
Covered Countries	USA \| CAN

Filter rows:

Showing 1 to 10 of 10 entries

Facility	City	State	Zip	Country	Details
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	48201	United States	Details
Local Institution - 0001	Seattle	Washington	98109	United States	Details
Local Institution - 0002	Portland	Oregon	97239	United States	Details
Local Institution - 0004	Boston	Massachusetts	02215	United States	Details
Local Institution - 0006	Houston	Texas	77030	United States	Details
Local Institution - 0007	Baltimore	Maryland	21205	United States	Details
Local Institution - 0010	Saint Louis	Missouri	63110	United States	Details
Local Institution - 0011	Vancouver	British Columbia	V5Z 4E6	Canada	Details
Local Institution - 0012	Toronto	Ontario	M5G 2M9	Canada	Details
Weill Cornell Medical College	New York	New York	10021	United States	Details

Showing 1 to 10 of 10 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field